Monday, 26 Aug 2019

You are here

Multiple Delays in Referral of New RA Patients

A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.

A total of 822 patients (563 female, mean age 55 years) were enrolled from 34 National Health Service trusts in England and Scotland, including networks such as the Early Rheumatoid Arthritis Network and the National Institute for Health Research Clinical Research Network. To be enrolled, adult patients had to have clinically apparent synovial swelling of one or more joints or a diagnosis of unclassified arthritis (UA) or new onset of RA (according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria.

Key findings included:

  • The median time between symptom onset and rheumatology consult was 27.2 weeks (IQR 14.1-66 weeks).
  • Only 20% of patients were seen within the first 3 months of symptom onset.
  • The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks).
  • The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks).
  • Patients had a mean of 4 GP visits before being referred.
  • The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Delays were prolonged in patients who purchased over-the-counter medications or used ice/heat packs took longer to seek help than those who did not.

Patients with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset.

The interval between first consultation with a rheumatologist and initiation of treatment was not measured in this study.

Multiple delays (patient, PCP, hospital, etc) contributed to a longer than expected time from symptom onset to rheumatologic evaluation. Patient education and delays by primary care providers will require interventions to promote more timely referrals.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

A Multidimensional Definition of Remission

A study from Leeds suggests 'multi-dimensional remission' (MDR) can be seen in one-third of RA patients achieving DAS28-remission; such patients have better patient-reported outcome measures, making it an optimal goal, especially from a patient's perspective.

Good Pregnancy Outcomes for DMARD Exposed JIA Patients

A study of pregnancy outcomes in 98 women with juvenile idiopathic arthritis (JIA) who were exposed to DMARDs shows no increased risk of major adverse pregnancy outcomes.

A total of 152 pregnancies in 98 women with JIA and 39 pregnancies involving 21 male patients as partners were reviewed. The majority had a polyarticular JIA (61%). The average age at first pregnancy was 24.1 years, and their mean disease duration was 13.8 years.

Autoantibodies Don't Disappear With Remission in RA

Immunologic remission in rheumatoid arthritis, defined as the disappearance of anti-citrullinated protein antibodies and rheumatoid factor, was seen infrequently among patients achieving sustained clinical remission and did not correlate with the disappearance of symptoms, a long-term Dutch study found.

Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease

Serologic testing is the principal means of laboratory diagnosis of Lyme disease. Current recommendations include using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay, followed by a western immunoblot assay for specimens yielding positive or equivocal results. On July 29, 2019, the Food and Drug Administration cleared several Lyme disease serologic assays with new indications for use, allowing for an EIA rather than western immunoblot assay as the second test in a Lyme disease testing algorithm. Thus, serologic assays that utilize a second EIA in place of western immunoblot assay are acceptable alternatives for the serologic diagnosis of Lyme disease.

Trends in Inflammatory Arthritis Care in Germany

The German National Database (NDB) has reviewed their experience in the care and quality of life of inflammatory rheumatic disease patients snce 1993, showing improved use of metrics, improved outcomes and a changing profile of biologic and anti-rheumatic drug use.